US “urgently” needs new ways to incentivise pharma

US policymakers need to urgently find new ways to incentivise pharmaceutical companies and device makers to develop products that produce more value, to help rein in massive healthcare spending, says a new report. To help reduce invention costs, the National Institutes of Health (NIH) – the major US funder of basic biomedical health – should encourage more creativity and risk-taking to promote major scientific breakthroughs, adds the study, from policy research group RAND Health.

Read the source article at PharmaTimes

About the Author

Leave a Reply